BNP Paribas Financial Markets Raises Stock Position in Chemed Corporation $CHE

by · The Markets Daily

BNP Paribas Financial Markets lifted its position in Chemed Corporation (NYSE:CHE – Free Report) by 14.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 35,024 shares of the company’s stock after buying an additional 4,430 shares during the period. BNP Paribas Financial Markets’ holdings in Chemed were worth $14,985,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of CHE. Geneos Wealth Management Inc. grew its position in shares of Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after buying an additional 76 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Chemed by 67.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company’s stock worth $5,534,000 after buying an additional 4,560 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Chemed in the 2nd quarter worth approximately $579,000. Brown Advisory Inc. grew its position in shares of Chemed by 36.9% in the 2nd quarter. Brown Advisory Inc. now owns 549 shares of the company’s stock worth $267,000 after buying an additional 148 shares during the last quarter. Finally, Cerity Partners LLC grew its position in shares of Chemed by 237.7% in the 2nd quarter. Cerity Partners LLC now owns 4,451 shares of the company’s stock worth $2,165,000 after buying an additional 3,133 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Chemed Stock Up 1.9%

NYSE:CHE opened at $440.67 on Friday. The company has a current ratio of 0.85, a quick ratio of 0.83 and a debt-to-equity ratio of 0.11. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $565.66. The company’s 50 day moving average is $409.41 and its two-hundred day moving average is $424.56. The company has a market cap of $5.85 billion, a PE ratio of 24.01, a P/E/G ratio of 1.66 and a beta of 0.54.

Chemed (NYSE:CHE – Get Free Report) last announced its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, beating the consensus estimate of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The business had revenue of $657.51 million during the quarter, compared to analysts’ expectations of $659.22 million. During the same period in the previous year, the business posted $5.63 EPS. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Analysts anticipate that Chemed Corporation will post 22.3 EPS for the current year.

Chemed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.5%. The ex-dividend date is Thursday, May 28th. Chemed’s payout ratio is presently 13.08%.

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the completion of the sale, the chief executive officer directly owned 90,219 shares in the company, valued at approximately $37,993,927.47. The trade was a 2.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 3.33% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada lifted their price objective on shares of Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a research report on Monday, April 27th. Oppenheimer dropped their target price on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings raised shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Chemed from a “hold” rating to a “buy” rating in a research report on Sunday, May 31st. Two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Chemed presently has a consensus rating of “Hold” and an average price target of $501.50.

Read Our Latest Analysis on Chemed

Chemed Company Profile

(Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

Featured Articles

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE – Free Report).